TABLE 3.

Schedule of Activities for the Diabetes Related to Acute Pancreatitis and Its Mechanisms (DREAM) Study

Assessment/Procedure	0 mo Enrollment	+3 mo (Metabolic Visit)	+6 mo	+12 mo	18 mo	24–60 mo (Annual)	New Diagnosis of DM
Research visit (Time window)	X (0–90 d after AP)	X (−2 to +6 wk)	X or * (−6 wk to +3 mo)	X (−3 to +3 mo)	X or (−3 to +3 mo)	X (±6 mo)
General
Demographics and medical history	X
Interim medical history		X	X	X	X	X	X
Height, weight, waist circumference	X	X		X		X	X
Questionnaires
Quality of life, EPI GI Symptom tracker	X	X		X		X
Food frequency questionnaire	X	X		X
Labs
FBG, HbA1c, autoantibodies	X	X	X	X	X	X
CBC with diff, creatinine, FE-1	X	X		X		X
Metabolic testing
OGTT		X
Serial OGTT arm				X		X	X (MMTT)
Serial MMTT arm†		X†		X		X	X
Serial FSIGTT arm†		X†		X			X (MMTT)
Imaging
Research MRI/MRCP‡		X		X		X3	X
Biorepository
Blood§	X	X		X		X	X
Stool||	X	X		X

The reference time point zero represents the date a participant first met the diagnostic criteria for their qualifying AP.

^* symbol indicates this visit could be conducted by telephone;

^†Serial MMTT and FSIGTT will be performed in a subset of participants. These tests will be offered to participants without DM at 3-mo visit;

^‡Research MRI/MRCP will be performed in a subset of participants through 36 mo;

^§Blood will be collected for serum, plasma, peripheral blood mononuclear cells, blood cell stabilizers (whole blood added to SmartTube Proteomic Stabilizer), Tempus tubes (RNAseq), and DNA (from a single blood collection);

^||Stool samples will be collected using methods that will allow microbiome and metabolic analyses.

diff indicates differential; EPI, exocrine pancreatic insufficiency; FBG, fasting blood glucose; FE-1, fecal elastase-1; GI, gastrointestinal; OGTT, oral glucose tolerance test; MMTT, mixed meal tolerance test; FSIGTT, frequently sampled intravenous glucose tolerance test.